A Big Tech Legislative Putsch Against Innovators


By Andrew Langer


Lawmakers are billing bipartisan legislation recently introduced on Capitol Hill as a compromise peace agreement in the ongoing policy war between startup innovators and Big Tech behemoths. In truth, however, the Patent Trial and Appeal Board Reform Act would lock in a massive victory for Big Tech.

Big Tech firms have increasingly tried to poach smaller rivals' technologies rather than licensing those ideas and paying royalties. Small inventors have fought back by suing in federal court for patent infringement. Many times, they've been completely vindicated and won big judgments.

Big Tech executives obviously don't enjoy paying out huge judgements, but neither are they willing to pay licensing fees if they can get away with helping themselves to the inventions of others. So they lobbied their allies in Congress to create a quasi-judicial body within the U.S. Patent and Trademark Office with authority to review and invalidate patents.

Lawmakers designed the Patent Trial and Appeal Board, the body in question, to operate in a way that favors Big Tech and other companies challenging the validity of existing patents on technicalities. The PTAB has at least partially invalidated 84% of patents in the cases it has reviewed and ruled on.

In theory, the PTAB is supposed to create a quicker avenue for challenges to patents that are so vague, they should never have been granted in the first place.

But in practice, Big Tech firms have weaponized the PTAB, filing repeated challenges in a desperate race to strike down their smaller rivals' patents -- before those patent holders can win their infringement lawsuits in court.

To rein in this abuse, the USPTO put new safeguards in place in 2018-2020. Most notably, the so-called Fintiv principles give the agency the flexibility not to initiate a PTAB review in certain circumstances, such as when the patent in question is already subject to ongoing litigation in federal courts.

This makes sense. Letting PTAB hear such challenges while companies are already duking it out in court would force inventors to defend against Big Tech's massively bankrolled assaults in two separate theaters. It's akin to double jeopardy.

Big Tech executives and their lobbyists have complained bitterly over the Fintiv principles, claiming it limits their ability to challenge "low-quality" patents.

There's scant evidence to support Big Tech's claims that the United States faces a growing epidemic of faulty patents. The rate of patent challenges has remained steady for a century: just 0.2% of patents approved by the USPTO are ultimately disputed.

USPTO's adoption of the Fintiv principles provided the reform PTAB urgently needed. So now Big Tech is looking to Congress to reverse Fintiv legislatively with the ironically named PTAB Reform Act. Doing so would reopen the floodgates to new patent-invalidation attempts before PTAB.

The "reform" legislation throws a few bones to the small inventors hauled before PTAB, calling for USPTO to pay for their legal representation before the board, at least in some cases. But its real purpose is to wedge the door open permanently for multiple duplicative patent challenges.

That's just what Big Tech wants. Lawmakers should reject this bogus compromise and let the Fintiv principles stand.

Andrew Langer is Chairman of the Institute for Regulatory Analysis and Engagement, a non-partisan, academic public policy organization dedicated to assessing the impacts of proposed rules and other regulatory proceedings on individual economic sectors and the U.S. economy as a whole. This piece originally appeared in Issues & Insights.



More Resources


05/02/2024
How Bad Is Biden Doing? He's Given Up on Bidenomics
President Biden skated past glaring stumbles and negative headlines because much of the media was laser focused on Donald Trump's trial in New York.

more info


05/02/2024
What Democrats Gain by Saving Speaker Johnson
The MAGA firebrand's attempt to remove the speaker has run into opposition from House Democrats playing the long game.

more info


05/02/2024
Washington Uniparty Wins, Americans Lose
The sham opposition of the institutional GOP leaves patriotic Americans desperate for real leadership from class traitors in Washington.

more info


05/02/2024
Could It Be 2016 All Over Again?
Revisiting the immigration-health care nexus.

more info


05/02/2024
Left-Wing Activists Met With WH on Registering Voters
New documents obtained by the Washington Examiner shed light on the White House's work with left-wing groups on voter registration.

more info


05/02/2024
The Many Faces of Campus Activism
The linkages between anti-war protesters and 317,000 students who waited a decade for restitution for their fraudulent college loans

more info


05/02/2024
Avoiding Victimhood: A Lesson From Our Jewish Peers
More than six months have passed since the deadly attacks of Oct. 7, 2023. Yet it seems like every day I wake up to new reports of antisemitic conduct, particularly among America's most elite young adults, Ivy League students. The latest has been a series of violent protests at Columbia and Yale where Jewish students were harassed and even attacked. At Penn, I have been reporting on the ground while protesters chanted "Israelis are pigs," and "Al-Qassam make us proud, take another soldier down." Our famous Ben Franklin statue was even vandalized with the KKK slur "Zios get fuckt." How did the...

more info


05/02/2024
DEI Conquers Stanford
The university now has at least 177 bureaucrats dedicated to left-wing racialism.

more info


05/02/2024
How To Tell Good Industrial Policy From Bad
Experience shows that encouraging exports rather than slapping tariffs on imports works best

more info


05/02/2024
Deceptive Climate Regulations Won't Stand in Court
If the major-questions doctrine doesn't kill them, the ‘rule against pretext' will.

more info


05/02/2024
The Greatest Health Challenge of the 21st Century
Since the dawn of the 20th century, humanity has experienced a rise in life expectancy unparalleled over our species' 300,000-year history. In 1900, a newborn could expect to live, on average, 32 years. By 2021, he or she had 71 years ahead of them.

more info


05/02/2024
Biden's Electoral College Challenge
President Joe Biden won a decisive Electoral College victory in 2020 by restoring old Democratic advantages in the Rust Belt while establishing new beachheads in the Sun Belt.

more info


05/02/2024
Unredactions Reveal White House Role in Trump Documents Case
Top Biden administration officials worked with the National Archives to develop Special Counsel Jack Smith's case against Donald Trump involving the former president's alleged mishandling of classified material, according to recently unsealed court documents in the case pending in southern Florida.

more info


05/02/2024
Student Unrest Ratchets Up an Already Tense Election Year
Dramatic campus protests are injecting an inflammatory new element into an election year that is already threatening to stretch national unity to a breaking point.

more info


05/02/2024
Campus Protests an Extension of BLM Riots 4 Yrs Ago
The Federalist's Mollie Hemingway on Wednesday's 'Special Report' addressed how the Biden White House is handling the Israel-Palestine conflict and anti-Israel protests across the nation.

more info



Custom Search

More Politics Articles:

Related Articles

5 Financial Pressure Points To Evaluate During COVID Times


Financial pressure is a part of life for most people, and now the COVID-19 pandemic has brought new financial pressure points or exacerbated existing ones for many individuals and families.

Why Are People Complaining About Innovative COVID Treatments?


Gilead Sciences just announced it will charge $3,120 for a full course of Remdesivir, the first new FDA-approved treatment for COVID-19. Some knee-jerk members of Congress like Lloyd Doggett (D-Tex.) immediately condemned that price tag as "outrageous." The Institute for Clinical and Economic Review, a left-leaning nonprofit that releases its own recommendations of "fair" drug prices, claimed that Gilead could afford to price Remdesivir as low as $10 per course of treatment -- the cost of the raw ingredients used to make the drug.

Proposed Healthcare Reforms Will Not Help the Latinx Community


Joe Biden is officially the Democratic presidential nominee, all thanks to his moderate reputation.

Trade Enforcement Can Accelerate America's Economic Recovery


The stock market has largely rebounded from COVID-19 and American retail sales are improving steadily. Even more encouraging is that the U.S. unemployment rate fell for the fifth consecutive month in September. Each of these gains are sure signs that the Trump administration's economic response to the coronavirus crisis is working.

Drug Price Controls: Right Objective, Wrong Solution


This month, President Trump signed an executive order to reduce Medicare spending on prescription drugs. For each medication, Medicare will pay no more than the lowest price available in other developed countries.

Keep Thanksgiving, Family and Friends Alive


Joe Biden or Donald Trump will never visit me in my home, stand beside me at the funeral home or dance at my wedding. I will not be receiving any calls from either of them to pray for me during sickness or to check on how my children are doing. I probably will never sit in a room with them to visit, laugh and tell funny stories or just to hang out over a cup of coffee. I do not personally know either one. I welcome the opportunity to visit with either of them, but doubt it will happen.

The "E" Stands for “Excellence:” Remembering Walter E. Williams


Walter E. Williams, prolific author, piercing cultural commentator, old school economist (that’s a good thing), devoted husband, loving father, and long-time friend of Grove City College has passed from this world.

How Congress Can Really Fix Surprise Billing


House and Senate leaders recently agreed on legislation to end surprise medical bills as part of a big coronavirus relief package. President Trump signed it into law at the end of December.

A Federal Rule Will Reverse Strides in Cancer Treatment


"You've got cancer." That's one of the scariest sentences in the English language.

Biden Must Restore Seniors' Access to Essential Medicines


On January 19, Medicare officials announced a new payment model that could wreak havoc on the chronically ill.

Violence In America, Don't Be Surprised


The most recent attack at the United States Capitol will most likely insure a permanent fence and additional security. The attack which resulted in the loss of life for a long serving Capitol police officer and the attacker is another senseless violent act.

Protecting the Innovation that Protects Global Health


The most far-reaching healthcare policy decision of 2021 won't be made in Congress or the White House. It will be made at the World Trade Organization, which is considering a petition to waive all patent rights on Covid-19 vaccines.

Don't Repeat Europe's Vaccine Catastrophe


For many Americans, the calamitously slow vaccine roll-out in countries like Germany, France, and Italy comes as a surprise. After all, in the early days of the pandemic, Europe's response to the crisis seemed highly competent, especially compared to the United States.

A Full Plate for the New U.S. Trade Czar


The newly confirmed U.S. trade representative, Katherine Tai, is about as qualified as a person can be for the job. Which is a good thing, because she already faces a series of challenges.

Don't Let the US Import Europe's Failed Cancer Policies


With a majority in both the House and Senate and control of the Oval Office, Democratic leaders are excited about the prospect of making significant changes. One good example of this is the House Democrats' "Lower Drug Costs Now Act."